心房颤动住院患者的抗凝治疗
摘要
心房颤动(房颤)患者脑卒中的年发生率平均为5%,不同亚组间差异很大0.5%~12%。房颤占所有脑卒中原因的15%~20%,在房颤基础上发生的卒中与无房颤患者相比,导致严重功能障碍和致死的比例更高^[1]。心房颤动(房颤)是缺血性卒中常见的危险因素,临床试验证实华法林能使非瓣膜房颤脑卒中的年发生率从4.5%下降至1.4%,且比阿司匹林更有效^[2]。
出处
《浙江临床医学》
2009年第11期1206-1208,共3页
Zhejiang Clinical Medical Journal
参考文献9
-
1Arboix A,GE Lluis, Massons JB, et al. Atrial fibrillation and stroke: clinical presentation of cardioembolic versus atherothrombotic infarction. Int J of Cardio1,2000 ,73 :33 - 42.
-
2Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation : executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences( Committee to Develop Guidelines for the Management of Patients With Atrial Fibfillation) :developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol,2001,38 : 1231 - 1266.
-
3Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age, distribution and gender of patients with atrial fibrillation. Arch Intern Med, 1995,155:469 - 473.
-
4Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation : incidence, risk factors, and prognosis in the manitoba follow - up study. Am J Meal,1995,98:476 -484.
-
5Deterson P, Boysen G, Godtfredsen J, et al. Placebo - controlled randomized trial of warfarin and Aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet,1989,1:175 - 179.
-
6Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med,2000,109:45 - 51.
-
7Petersen P, Boysen G, Godtfredsen J, et al. Placebo - controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study, lancet, 1989,1 ( 8631 ) : 175 - 179.
-
8The SPAF Ⅲ Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention inAtrial Fibrillation ⅢStudy. JAMA,1998,279(16) :1273 - 1277.
-
9戚文航.中国部分地区心房颤动住院病例回顾性调查[J].中华心血管病杂志,2003,31(12):913-916. 被引量:380
共引文献379
-
1顾智淳,张在丽,刘晓琰.1例胺碘酮致华法林国际标准化比值升高的病例分析[J].医药导报,2015,34(S01):172-173. 被引量:1
-
2卢建平.96例老年心房颤动患者的临床诊疗体会[J].临床研究,2014,22(11):29-29.
-
3龚冰璐,黄红漫.心房颤动的基础研究和临床治疗新进展[J].心血管病学进展,2006,27(z1):106-108.
-
4赵琼琼,柳茵.高血压伴心房颤动患者脑钠肽的变化与肾素血管紧张素醛固酮系统的关系[J].青海医药杂志,2008,38(4):1-3. 被引量:3
-
5杜昕,胡荣,康俊萍,韩智红,刘晓惠,董建增,马长生.心房颤动门诊病例的调查[J].中国心脏起搏与心电生理杂志,2004(z1).
-
6舒燕,陈晓平.血管紧张素受体拮抗剂对心房纤颤的影响[J].华西医学,2008,23(5):1201-1202. 被引量:2
-
7罗蔓,谢瑞满,全洪波,胡予,蔡映云.非瓣膜病性心房颤伴缺血性卒中生存与复发因素分析[J].中国老年保健医学,2007,5(4):9-12.
-
8谢百福.胺碘酮联合小剂量氟伐他汀治疗阵发性房颤的临床观察[J].中国实用医药,2007,2(33):131-132. 被引量:3
-
9杜萍.心理干预对老年心房颤动患者负性情绪的影响[J].中华现代护理杂志,2007,13(30):2883-2884. 被引量:2
-
10黄飞翔.心房颤动的中西医抗凝治疗[J].中国中医急症,2004,13(11):749-750. 被引量:1
-
1李琚平.老年非瓣膜房颤患者华法林抗凝治疗的可行性及抗凝强度的探讨[J].中国继续医学教育,2015,7(12):171-172. 被引量:7
-
2郑立文,刘晨,文应峰,杨宗辉.华法林对老年非瓣膜房颤抗凝疗效及安全性评价[J].中国老年学杂志,2011,31(14):2739-2740. 被引量:23
-
3张乃奇.华法令预防非瓣膜性房颤患者并发脑梗塞的临床分析[J].中外医学研究,2012,10(7):32-33. 被引量:9
-
4梅宝英.老年非瓣膜房颤患者应用华法林的安全性评价[J].中国实用医刊,2013,40(5). 被引量:6
-
5雷刚.华法林抗凝治疗老年非瓣膜房颤的疗效及安全性[J].心血管病防治知识(学术版),2014,4(2):75-76. 被引量:3
-
6许春艳,赵东升,何平,于春波,王兴华.非瓣膜心房颤动临床特征分析[J].现代中西医结合杂志,2011,20(7):842-842.
-
7陈元友.华法林对老年非瓣膜房颤抗凝的临床价值[J].现代养生,2015,0(20):51-51.
-
8汉迪,王悦喜.非瓣膜房颤相关因素分析及预防血栓栓塞研究[J].内蒙古医学杂志,2009,41(5):577-579. 被引量:1
-
9张优惕,张小河.华法林抗凝治疗对老年非瓣膜房颤的可行性分析[J].当代医学,2014,20(14):130-131. 被引量:3
-
10卢燕玲,张金荣.老年慢性非瓣膜房颤患者的抗凝治疗[J].中华急诊医学杂志,2006,15(1):54-56. 被引量:5